| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; and
Department of Medicine, Division of Oncology, University of Washington Medical Center, Seattle, WA 98195
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-chain receptor cytokine family (that includes IL-2, IL-7, and IL-15), has been described as an important regulator of the cellular immune response. In this study, the role of IL-21 in the generation of a human Ag-specific CD8+ T cell response is characterized by tracking a rare, but measurable population of self-Ag-specific T cells in vitro. Autologous dendritic cells pulsed with the melanoma antigen recognized T cells 1 self-peptide were used to stimulate CD8+ T cells from HLA-A2+ healthy donors and melanoma patients. We demonstrate that exposure to IL-21 increased the total number of MART-1-specific CD8+ T cells that could be elicited by >20-fold and, at the clonal level, enriched for a population of high-affinity CD8+ T cells with a peptide dose requirement more than 1 log10–fold less than their untreated counterparts. Phenotypic analysis of T cells from IL-21-treated cultures revealed a unique population of CD45RO+CD28highCD8+ T cells, a phenotype that was stable for at least 4 wk after IL-21 exposure. These CD28highCD8+ T cells produced IL-2 upon Ag stimulation and represent potential helper-independent CTLs. Our studies demonstrate a significant role for IL-21 in the primary Ag-specific human CTL response and support the use of IL-21 in the ex vivo generation of potent Ag-specific CTLs for adoptive therapy or as an adjuvant cytokine during in vivo immunization against tumor Ags. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-chain receptor cytokine family (IL-2, IL-7, IL-15) (1, 2, 3) and appears to share many of the properties associated with T and NK cell activation and differentiation. In murine studies, IL-21 potentiates the maturation and effector function of NK cells and promotes T cell activation in response to alloantigen (4). As a cytokine which limits NK cell expansion and promotes activation of murine CD8 T cells, IL-21 is believed to play a role in the transition from innate to adaptive immunity (4). Among CD4 T cells, IL-21 has been described as both a Th1cytokine which up-regulates the expression of genes associated with innate immunity (5) as well as a Th2 cytokine that inhibits the differentiation of naive Th cells into IFN--producing Th1 cells (6). The effects of IL-21 in the development of innate immunity and CD4 Th responses are well characterized (5, 7), but its role in the priming of an Ag-specific CD8+ T cell response, particularly in humans, has not been fully explored. This is due in part to limitations in detecting and tracking low-frequency Ag-specific responses among naive T cells in a nontransgenic model. Although responses to most self-Ags (such as gp100 and NY-ESO-1) can provide examples of a naive response, they often exist in very low frequency; the most accessible population is represented by melanoma antigen A/melanoma antigen recognized by T cells (MART-1)3 specific CTLs which, in the healthy unprimed individual, has been characterized phenotypically and functionally as naive T cells (8, 9). In this study, we characterize the role of IL-21 in the induction of Ag-specific human CD8+ T cell responses using peptide-MHC tetramers to track a rare but measurable population of CTL precursors recognizing a self-Ag (9). We find a potent effect of IL-21 in generating a high-affinity Ag-specific CTL response that exceeds by >20-fold, that which can be achieved in control cultures. Induction of a high-affinity CD8 response against self-Ags, which are represented increasingly as potential immune targets in cancer immunotherapy predict a significant role for IL-21 in Ag-specific antitumor strategies.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Melanoma cell lines A375 (gift from S. Rosenberg, NCI, Bethesda, MD) and Mel 526 (gift from M. Lotze, University of Pittsburgh, Pittsburgh, PA) were maintained in RPMI 1640 with 25 mM HEPES, 4 mM L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, 10 mM sodium pyruvate, 1 mM nonessential amino acids, and 10% FBS (HyClone). Both lines express the HLA-A2 allele, but only Mel 526 expresses the MART-1 Ag. The T2 cell line is a TAP-deficient T-B cell hybrid expressing the HLA-A2 allele. EBV-lymphoblastoid cell lines (LCL) are EBV-transformed lymphoblastoid cell lines established in our laboratory.
Induction of human Ag-specific CD8+ T cells
Melanoma M27-35 (AAGIGILTV) peptide-specific T cells were generated in a manner similar to that previously described (10, 11, 12). Donor blood was typed by the HLA Typing Laboratory at the Puget Sound Blood Center (Seattle, WA). CD8+ T cells were first isolated by a CD8-positive isolation kit (Dynabeads; Dynal) from leukapheresis PBMCs, suspended in CTL medium consisting of RPMI 1640, 25 mM HEPES, 2 mM L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin (Invitrogen Life Technologies), and 10% human serum from normal donors, and then placed in 6-well tissue culture dishes (Costar) at 6 x 106 cell/well. Mature dendritic cells (DCs) were harvested and pulsed with 40 µg/ml synthesized peptides at 2 x 106 cell/ml in the presence of 3 µg/ml 
2-microglobulin (The Scripps Laboratory, San Diego, CA) in PBS with 1% human serum albumin (Invitrogen Life Technologies) for 4 h at room temperature. After washing three times with sterile PBS (Invitrogen Life Technologies), DCs were mixed with purified CD8 T cells at 3 x 105 cells/well in 6-well plates. Cytokines, IL-15 (10 ng/ml; R&D Systems), IL-2 (10 U/ml; Chiron), IL-7 (10 ng/ml; R&D Systems), or IL-21 (30 ng/ml; Zymogenetics) were added individually to each well immediately after the culture was initiated. IL-2 (50 IU/ml) and IL-7 (10 ng/ml) were added 1 day after the second stimulation to further facilitate expansion of activated Ag-specific T cells.
DCs were generated as previously described (13) by exposing adherent PBMCs to IL-4 (500 U/ml; R&D Systems) and GM-CSF (800 U/ml; Amgen) in AIM-V medium (Invitrogen Life Technologies) followed by maturation using IL-1 at 2 ng/ml, IL-6 at 1000 U/ml, TNF-
at 10 ng/ml (R&D Systems), and PGE2 at 1 µg/ml (Sigma-Aldrich) for an additional 2 days. The mature DC population contained >90% CD83+ DCs on day 8 as determined by FACS analysis.
Ab plus peptide-MHC tetramer staining of T cells
PE- or allophycocyanin-labeled M27-MHC-tetramer and G154-MHC-tetramers were produced in the immune monitoring laboratory at the Fred Hutchinson Cancer Center based on previously described protocols (14). For sample analysis, 0.5 x 106 cells in 25 µl of 2% FCS/PBS were first stained with peptide tetramer-PE or allophycocyanin (final concentration of 20 µg MHC/ml) for 1 h at room temperature, followed by anti-CD28-allophycocyanin (BD Pharmingen) or anti-CD28-FITC (Caltag Laboratories), anti-CCR7-PE, and anti-CD45RO or anti-CD45RA-FITC (BD Pharmingen) staining for 20 min at 4°C. After washing with PBS, cells were resuspended in PBS containing 2% FBS and 4',6'-diamidino-2-phenylindole was added. Data were acquired using a FACSCalibur flow cytometer and CellQuest (BD Biosciences) and analyzed using FlowJo software (TreeStar).
Enrichment for naive and memory subsets
T cells were purified from human PBMCs by the sequential application of a combination of magnetic beads and an AutoMACS Magnetic Sorter (Miltenyi Biotec). CD8+ cells were isolated using negative selection with the CD8 isolation kit II. Subsequent naive (CD8+CD45RO–CD45RA+CD62L+) cell selection involved depletion of memory CD8 cells using a CD45RO bead, followed by positive selection of CD62L-positive cells by staining with PE-conjugated CD62L Ab (BD Pharmingen) and incubation with an anti-PE bead. Memory cell isolation (CD8+CD45RA–CD45RO+) involved depletion of the naive population with a CD45RA+ bead. Typical purities assessed by FACS were in excess of 95%.
Cloning and expansion of Ag-specific CTLs
The cloning and expansion procedures were identical to that previously described (10, 15). Tetramer-positive sorted T cells were plated at limiting dilution in 96-well round-bottom plates (Nalge Nunc International) in the presence of irradiated feeder cells (PBLs and LCLs) at a responder:stimulator ratio of 1:50,000 along with anti-CD3 mAb (OKT3; Ortho Tech) and 50 U IL-2/ml in 0.2 ml of CTL medium. Wells positive for clonal growth were identified 10–14 days after plating and screened in a microcytotoxicity assay. Peptide-specific clones were transferred to 25-cm2 flasks (Costar), restimulated with anti-CD3 mAb, and irradiated allogeneic PBLs and LCLs were added as feeder cells for rapid expansion. The cultures were fed with IL-2 at 50 U/ml 24 h after restimulation and then every 3 days. After 14 days, cells were used for further analyses or cryopreserved.
In vitro cytotoxicity assay
Target cells (375, 526 melanoma cell lines, or T2 cells) were labeled with 100 µCi of 51Cr and cocultured with effector cells for 4 h at 37°C plus 5% CO2. For peptide dose titration studies, T2 were pulsed with a peptide at concentrations ranging from 101 to 107 pg/ml for 1 h and then washed before 51Cr labeling. Released 51Cr was measured with a gamma scintillation counter and percent specific lysis was determined by using the formula: percent specific release = experimental release – spontaneous release/total release. Spontaneous release was <10% of the total release in all assays.
MHC/peptide dissociation assay to identify high-and low-affinity CTL clones
CTL clones were stained with allophycocyanin-tetramer (20 µg/ml) for 1 h at room temperature and washed once with cold PBS to eliminate unbound tetramer. Cells were incubated in the presence of an excess (100 µg/ml) of PE-labeled tetramer to prevent rebinding of allophycocyanin-tetramer after their dissociation from TCR. During this period, aliquots of cells were collected at different time points and fixed in 1% paraformaldehyde for flow cytometry analysis. The rate of APC tetramer dissociation is inversely correlated with TCR affinity (16).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
A model system for primary in vitro stimulation of Ag-specific T cells was established by isolating CD8+ T cells from PBMCs of HLA A2+ healthy donors and coculturing with autologous mature DCs pulsed with immunogenic epitopes of the tumor-associated self-Ag, MART-1 (M27-35 peptide). Cultures were grown with no added cytokine or with increasing doses of IL-21 (0.1–100 ng/ml). Following in vitro stimulation, IL-21-mediated augmentation of Ag-specific CTL was not observed below a concentration of 10 ng/ml, was optimal at 30 ng/ml, and inhibitory at 100 ng/ml (Fig. 1). The reason for the inhibition at 100 ng/ml is not clear, but at this concentration, IL-21 may have a counterregulatory effect associated with its role as a Th2 cytokine (6). A concentration of 30 ng/ml was used in subsequent studies.
|
-chain cytokine receptor family was also compared with IL-21. IL-2, IL-7, and IL-15 at their respective optimal concentrations produced no added effect on the frequency of MART-1-specific CD8+ T cells compared with no cytokine control cultures during primary in vitro stimulation (Fig. 2).
|
|
One practical outcome of these studies would be the capacity to augment tumor-associated Ag-specific CTL responses in patients with melanoma, a tumor which shares expression of MART-1. In a representative patient, the frequency of MART-1-specific CTLs generated in IL-21-treated compared with untreated cultures after two cycles of in vitro stimulation demonstrate a 40-fold increase when IL-21 was added compared with untreated controls (19.0 vs 0.34%; Fig. 3C, patient ST).
To evaluate whether the increase in frequency and absolute numbers of Ag-specific CD8 T cells generated among IL-21-treated cultures was due to enhanced proliferation and/or enhanced survival, naive CD8 T cells were labeled with CFSE, stimulated in vitro with MART-1 peptide-pulsed autologous DCs and, at day 7, evaluated for fraction of dividing cells (as determined by quantum decreases in CFSE staining accompanying each cell division) and apoptosis (annexin V staining). For CFSE staining, analyses performed on the tetramer-positive (MART-1-specific) T cell population demonstrate a substantially greater fraction of nondividing cells (rightmost compartment) among untreated cultures (44%) than IL-21-treated cultures (18%; Fig. 4). In fact, the ratio of rapidly dividing (leftmost compartment) to nondividing Ag-specific T cells is >3-fold greater among the IL-21-treated compared with the untreated cultures (63 (18%) vs 36 (44%)). That the effect of IL-21 on T cell proliferation is Ag specific is demonstrated by the large fraction of tetramer-negative (non-Ag specific) T cells remaining in the nondividing phase (95.6 and 87.9%).
|
IL-21 enhances Ag-specific T cell response among a predominantly naive CTL population
The capacity of IL-21 to enhance the generation of Ag-specific CD8+ T cells was evaluated separately among naive and memory T cells. Purified populations of naive (>98% CD45RA+CD62L+) CD8+ T cells were compared with memory (100% CD45R0+) CD8+ T cells from both a healthy normal donor (donor CG) (Fig. 5) and an individual with metastatic melanoma (patient ST). Whereas IL-21 exerts minimal effect on the frequency of MART-1-specific cells generated from memory CD8+ T cells (0.10–0.15% and 0.05–0.037%), a 12- to 90-fold increase is observed among naive CD8 T cells following IL-21 exposure (0.94–12.5% and 0.08–7.08%), suggesting that IL-21 influences primarily naive T cells.
|
To further characterize the function of Ag-specific T cell populations generated under the influence of IL-21 at the clonal level, tetramer-positive CD8+ T cells from both a healthy donor (donor CG) and melanoma patient (patient ST) were sorted on day 7 and cloned at limiting dilution into 96-well plates. MART-1-specific clones identified by microcytotoxicity assays were expanded and tested for 1) the peptide concentration required for 50% maximal lysis (P50) of peptide-pulsed T2 cells and 2) the ability to lyse Ag-positive melanoma targets. For evaluating P50, the HLA-A2-transfected EBV B cell line T2 was titrated with peptide concentrations ranging from 107 to 102 pM. Results are presented as the peptide dose requirement (nanomolar) for 50% lysis (P50). CTL clones generated from IL-21-treated cultures required a >1 log lower peptide dose requirement than their untreated counterparts, mean 3 nM (range, 0.6–30 nM) vs mean 80 nM (range, 16–500 nM), respectively (Fig. 6A). A similar effect of IL-21 was seen for CTL clones generated from melanoma patient S.T. (Fig. 6B).
|
That the increased tumor avidity is attributable to a higher affinity TCR and not other accessory factors can be demonstrated using tetramer-based TCR staining assays. Although the intensity of tetramer staining can generally be correlated with TCR affinity (11, 17), a more precise definition of TCR affinity can be obtained based on the rate of tetramer dissociation, Kd, from its specific TCR ligand (16). In this assay, the Kd of the TCR-peptide-MHC interaction or TCR affinity is inversely correlated with the fraction of bound tetramer remaining over time in the presence of an excess of unlabeled tetramer. CTL clones elicited from IL-21-treated or untreated cultures were stained with M27 peptide-tetramer-PE and incubated with excess unlabeled M27-tetramer. The fraction of tetramer-bound CTLs was determined by flow cytometry at specified time points (2–60 min). TCR/tetramer-peptide off rates were found to be significantly faster for clones isolated from untreated cultures compared with clones generated in IL-21-treated cultures (Fig. 7). Taken together, these results demonstrate that IL-21 treatment leads to the generation of T cells clones expressing high-affinity TCR.
|
expression among the cohort of high- and low-affinity T cell clones using a panel of anti-V Abs. For example, for patient C.G., among nine high-affinity T cell clones, seven expressed unique V chains (only two shared V expression) and a similarly diverse TCR repertoire was observed among the group of low-affinity T cell clones in this patient (among 10 different low-affinity clones, only 2 shared the same V), suggesting that the effect of IL-21 was not due merely to the expansion of an oligoclonal population of high-affinity T cell clones in vitro (Table I).
|
CTLs recognizing the self-Ag MART-1 are present at very low frequency (0.0–0.5% by tetramer staining) in the peripheral blood of donors and are usually characterized by a naive phenotype expressing CD45RA+(CD45RO–), CCR7+, and CD28int (9) (Fig. 8, Pre-Stimulation). About one-half of these precursors (42%) express intermediate levels of CD28 and nearly 50% are CCR7+. We examined the differentiation phenotype of this rare but measurable population of naive T cells under the influence of IL-21. In IL-21-treated or untreated cultures, in vitro Ag-specific stimulation results in a shift from CD45RA+ to predominantly CD45RO+ expression (Fig. 8, Post-Stimulation). As expected, Ag stimulation is also accompanied by a decrease in CCR7 expression. In IL-21-treated cells however, the level of CD28 expression remained high compared with untreated control cells and this CD45RO+CD28high phenotype among IL-21-treated CD8+ T cells persisted at least 4 wk after primary in vitro stimulation (Fig. 8). This up-regulation of CD28 expression was observed in both naive healthy donors and melanoma patients for both MART-1- and gp100-specific CTLs.
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-chain receptor cytokine since the addition of IL-2, IL-7, or IL-15 during initial priming had no added effect over cultures that received no cytokine. IL-21-exposed and Ag-primed T cells retained the capacity to respond to growth-promoting cytokines, such as IL-2 and IL-7 and could be readily isolated and expanded. We found that the effect of IL-21 to augment the Ag-specific response was limited to the naive and not memory T cell population using preselected responder T cells. One explanation may be that a larger number of MART-1-specific T cells reside among the naive population (9). However, measurable frequencies of MART-1-specific T cells can also be detected among the memory population (Fig. 3 and Ref. 18) and yet these failed to expand when IL-21 was added. Since equivalent levels of IL-21 receptor (as determined by quantitative RT-PCR) are expressed in naive and memory CD8+ T cells (our unpublished data), downstream signaling events may account for this difference. In the case of patients with melanoma, a previous encounter with Ag-bearing tumor cells may lead to defective signaling among memory T cells rendering them unresponsive to IL-21 mediated proliferation in vitro (19, 20).
Although the molecular events responsible for an enhanced Ag-specific T cell response have yet to be defined, Ag-primed T cells do undergo increased proliferation and decreased apoptosis when exposed to IL-21 compared with their untreated counterparts. IL-21 treatment led to up-regulated CD28 expression and enriched for a population of T cells expressing a stable unique phenotype, CD45RO+, CD28high, CCR7–CD8+, that may be characterized as intermediate between a naive (CD45RO–CD28+CCR7+) and memory (CD45RO+CD28–CCR7–/+) T cell (21). Enhanced proliferation and survival secondary to CD28 costimulation may have contributed to the greater numbers and prolonged survival of Ag-specific CTLs elicited during the primary response among IL-21-treated cultures. Since helper-independent, Ag-driven CD28+CD8+ T cells represent potentially more effective CTLs for adoptive immunotherapy, understanding the mechanism of IL-21-mediated up-regulation of CD28 in human CD8 T cells may allow us to manipulate and expand a population of helper-independent T cell clones for adoptive immunotherapy without the requirement for genetic modification (22).
Exposure to IL-21 during primary in vitro stimulation also led to the generation of Ag-specific T cell clones of uniformly higher affinity and target cell avidity. These clones were represented by diverse TCR Vs, suggesting that this was not likely the result of an expanded population of a few high-affinity clones, but a more global effect on the T cell repertoire. Since the IL-21 receptor is expressed on both DCs used for stimulation and the responder T cells, it is unclear which cell type is responsible for this phenomenon. Previous studies have shown an increased probability of isolating higher affinity T cell clones when cytokines such as IL-10, that down-regulate the stimulatory capacity of APCs, are used in culture (23). In this case, a dampened stimulatory capacity may enrich for a population of higher affinity CTLs. For IL-21, Brandt et al. (24) have shown recently that IL-21 leads to maturational arrest among murine DCs, resulting in reduced MHC expression and decreased stimulatory capacity for T cell activation. However, in our studies, IL-21 was added to human DCs that had already undergone full maturation. In preliminary studies, we found that the addition of IL-21 to mature DCs did not affect surface expression of MHC class I, HLA-DR, CD80, CD83, or CD86 compared with untreated DCs, suggesting that dampened expression of surface stimulatory molecules is not likely an explanation for the enhanced generation of high-affinity T cells in vitro. Preincubation of mature human DCs with IL-21 also had no effect on the frequency or affinity of CD8+ tetramer-positive T cells that could be generated (data not shown). Methods that prevent IL-21 engagement on either T cells or DCs, for example, preincubation with anti-IL-21 receptor Abs as these become available or the use of receptor-negative APCs may shed some light on the cell type responsible for this observation.
The use of IL-21 in augmenting an Ag-specific CD8 T cell response has been explored in mouse models and found to be highly effective in eradicating aggressive tumors (25, 26, 27). The selective effect of IL-21 in our study on naive vs memory T cells suggests a greater influence during priming, and, in fact, murine studies demonstrate a strong priming effect characterized by a slow rejection response and induction of prolonged antitumor memory. IL-21 appeared to promote long-term survival of previously activated Ag-specific CD8 T cells in vivo as a result of reduced apoptosis through an indeterminate mechanism possibly involving STAT3 phosphorylation or induction of a central memory phenotype (28). In our studies, some of these effects may be attributable to CD28 up-regulation among IL-21-treated CD8 T cells.
In conclusion, our data indicate that IL-21 enhances the generation of human Ag-specific CD8+ T cells characterized by CD28 up-regulation and expression of high-affinity TCR resulting in Ag-driven helper-independent IL-2 production, increased target avidity, and augmented Ag-specific tumor killing. The results of our in vitro studies suggest that IL-21 plays positive role in the induction of a human Ag-specific CD8 T cell response and support the use of this cytokine in immunotherapeutic strategies.
|
Acknowledgments |
|---|
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 C.Y. is a Damon Runyon-Lilly Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation. This work was also supported by the Fialkow Award and the General Clinical Research Center at the University of Washington, Grant No. M01-RR00037. 
2 Address correspondence and reprint requests to Dr. Cassian Yee, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D3-100, Seattle, WA 98109. E-mail address: cyee{at}fhcrc.org
3 Abbreviations used in this paper: MART-1, melanoma antigen recognized by T cells 1; DC, dendritic cell; LCL, lymphoblastoid cell line.
Received for publication November 5, 2004. Accepted for publication June 7, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167: 1-5. production in human NK and T cells. J. Immunol. 170: 5464-5469. -producing Th1 cells. J. Exp. Med. 196: 969-977. regulates IL-21 and IL-21R expression in human NK and T cells. J. Leukocyte Biol. 76: 416-422. . J. Immunol. 171: 608-615. This article has been cited by other articles:
|
|
 |
|
  S. Ansen, M. O. Butler, A. Berezovskaya, A. P. Murray, K. Stevenson, L. M. Nadler, and N. Hirano Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21 Clin. Cancer Res., October 1, 2008; 14(19): 6125 - 6136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 N. Engl. J. Med., June 19, 2008; 358(25): 2698 - 2703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Iuchi, S. Teitz-Tennenbaum, J. Huang, B. G. Redman, S. D. Hughes, M. Li, G. Jiang, A. E. Chang, and Q. Li Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral Responses Cancer Res., June 1, 2008; 68(11): 4431 - 4441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Hinrichs, R. Spolski, C. M. Paulos, L. Gattinoni, K. W. Kerstann, D. C. Palmer, C. A. Klebanoff, S. A. Rosenberg, W. J. Leonard, and N. P. Restifo IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy Blood, June 1, 2008; 111(11): 5326 - 5333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw Interleukin 21 Enhances Antibody-Mediated Tumor Rejection Cancer Res., April 15, 2008; 68(8): 3019 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li and C. Yee IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes Blood, January 1, 2008; 111(1): 229 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Davis, K. Skak, M. J. Smyth, P. E.G. Kristjansen, D. M. Miller, and P. V. Sivakumar Interleukin-21 Signaling: Functions in Cancer and Autoimmunity Clin. Cancer Res., December 1, 2007; 13(23): 6926 - 6932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yang, E. M. Wall, K. Milne, P. Theiss, P. Watson, and B. H. Nelson CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism Clin. Cancer Res., December 1, 2007; 13(23): 7172 - 7180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Barker, J. G. Parvani, D. Meyer, A. S. Hey, K. Skak, and N. L. Letvin IL-21 Induces Apoptosis of Antigen-Specific CD8+ T Lymphocytes J. Immunol., September 15, 2007; 179(6): 3596 - 3603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ostiguy, E.-L. Allard, M. Marquis, J. Leignadier, and N. Labrecque IL-21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade J. Leukoc. Biol., September 1, 2007; 82(3): 645 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Davis, B. K. Skrumsager, J. Cebon, T. Nicholaou, J. W. Barlow, N. P. H. Moller, K. Skak, D. Lundsgaard, K. S. Frederiksen, P. Thygesen, et al. An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma Clin. Cancer Res., June 15, 2007; 13(12): 3630 - 3636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. White, S. Krishnan, N. Strbo, H. Liu, M. A. Kolber, M. G. Lichtenheld, R. N. Pahwa, and S. Pahwa Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV) Blood, May 1, 2007; 109(9): 3873 - 3880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Coquet, K. Kyparissoudis, D. G. Pellicci, G. Besra, S. P. Berzins, M. J. Smyth, and D. I. Godfrey IL-21 Is Produced by NKT Cells and Modulates NKT Cell Activation and Cytokine Production J. Immunol., March 1, 2007; 178(5): 2827 - 2834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cappuccio, M. Elishmereni, and Z. Agur Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res., July 15, 2006; 66(14): 7293 - 7300. [Abstract] [Full Text] [PDF]
|
|
| |||||
). These same clones were evaluated for specific reactivity to a MART-1+ tumor cell line (526) at E:T ratio of 10:1 in a standard 4-h 51Cr release assay. Significantly greater lysis of Ag-positive tumor (526: • and 
) with background lysis of Ag-negative tumor (375: 
and 
